Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-05-10
2011-05-10
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S235100, C530S350000
Reexamination Certificate
active
07939082
ABSTRACT:
A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus L1 protein or a combination of papilloma virus L1 protein and papilloma virus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs.
REFERENCES:
patent: 4551270 (1985-11-01), Danos et al.
patent: 5045447 (1991-09-01), Minson
patent: 5071757 (1991-12-01), Kreider et al.
patent: 5437951 (1995-08-01), Lowy et al.
patent: 6613557 (2003-09-01), Frazer et al.
patent: 7169585 (2007-01-01), Frazer et al.
patent: 7476389 (2009-01-01), Frazer et al.
patent: WO 91/04330 (1991-04-01), None
patent: WO 92/16638 (1992-10-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 94/00152 (1994-01-01), None
patent: WO 94/05792 (1994-03-01), None
patent: WO 94/20137 (1994-09-01), None
Summers et al., “A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures,” Texas Agricultural Experiment Station Bulletin No. 1555 (1987).
Zhou et al., “Increased Expression of Vaccinia Recombinant HVP 16 L1 and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Virion Like Particles,” J. Gen. Virology, 1990, pp. 2185-2190, vol. 71.
Zhou et al., “Increased antibody responses to human papillomavirus type 16 L1 protein expressed by Recombinant vaccine virus lacking serine protease inhibitor genes,” Chemical Abstracts, Nov. 5, 1990, vol. 13, No. 19.
Zhou et al., “Human Papillomavirus Type 16 Virions Produced by a Recombinant Vaccinia Virus” Abstract from 1991 Papillomavirus Workshop (Seattle, WA 1991).
Zhou et al., “Definition of Linear Antigenic Regions of the HPV 16 L1 Capsid Protein Using Synthetic Virion-like Particles”Virology, 189:592-599 (1992).
Article entitledIncreased Antibody Responses to Human Papillomavirus Type 16 L1 Protein Expressed by Recombinant Vaccina Virus Lacking Serine Protease Inhibitor Genes, from Chemical Abstract, vol. 13, No. 19, issued Nov., (1990).
International Search Report for PCT/AU92/00364, (1992).
Article entitledExpression of Vaccinia Recombinant HPV 16 L1 and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Virion-Like Particles, from Virology, vol. 185, No. 1, 1991.
International Application PCT/NL90/00130 filed Sep. 11, 1990 by Rijksuniversiteit Te Leiden.
Galloway, Journal of the National Cancer Institute, 86:474-475, (1994).
Tomita et al.,Journal of Virology, 61:2389-2394, 1987.
Icenogle et al.,Virology, 184:101-107, Sep. 1991.
Chen et al.,Journal of General Virology, 79:2137-2146, 1998.
Zhou et al.,Virology, 185(1): 251-257, 1991.
Office Action dated Jun. 26, 2008 by the Examiner in U.S. Appl. No. 11/455,236 (US 2007/0154902).
Baker, “Sequence Analysis of Papillomavirus Genomes”The Papovaviridae, vol. 2—The Papillomaviruses, Salzman and Howley, Eds., Plenum Press (1987).
Baker et al., “Structures of bovine and human papillomaviruses”Biophys. J., 60:1445-1465 (1991).
Browne et al., “Analysis of the L1 Gene Product of Human Papillomavirus Type 16 by Expression in a Vaccinia Virus Recombinant”J. Gen. Virol., 69:1263:1273 (1988).
Carter et al., “Expression of Human Papillomavirus Proteins in YeastSaccharomyces cerevisiae” Virology, 182:513-521 (1991).
Cole et al., “Nucleotide Sequence and Comparative Analysis of the Human Papillomavirus Type 18 Genome,”J. Mol. Biol., 193:599-608 (1987).
Finch et al., “The Structure of Viruses of the Papilloma-Polyoma Type,”J. Mol. Biol., 13:1-12 (1965).
Galloway,Journal Of The National Cancer Institute, 1994, pp. 474-475, vol. 86, No. 7.
Hagensee et al., “Self-Assembly of Human Papillomavirus Type 1 Capsids by Expression of the L1 Protein Alone or by Coexpression of the L1 and L1 Capsid Proteins”J. Virology, 67:315-322 (1993).
Kirnbauer et al., “Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic”Proc. Natl. Acad. Sci. USA, 89:12180-12184 (1992).
Kirnbauer et al., “Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-Like Particles”J. Virology, 67:6929-6936 (1993).
Rose et al., “Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles”J. Gen. Virology, 71:2725-2729 (1990).
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nded., Cold Spring Harbor Laboratory Press (1989).
Seedorf et al., “Human Papillomavirus Type 16 DNA Sequence”Virology, 145:181-185 (1985).
Sterling et al., “Production of Human Papillomavirus Type 16 Virions in a Keratinocyte Cell Line”J. Virology, 64:6305-6307 (1990).
Office Action issued Jun. 26, 2008, in U.S. Appl. No. 11/455,236, 10 pages.
Frazer Ian
Zhou Jian
CSL Limited
Foley & Lardner LLP
Mosher Mary E
The University of Queensland
LandOfFree
Papilloma virus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Papilloma virus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Papilloma virus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664584